

New dialyzer approved by FDA

Stockholm, Sweden, November 8, 2000 - Gambro AB (OM Stockholm Exchange: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that it has received approval by the US Food and Drug Administration, FDA, for a synthetic dialyzer for reuse applications.

Initially, the dialyzer is primarily intended for Gambro's own clinics within Gambro Healthcare. It will rapidly replace external sourcing of reuse dialyzers and is part of Gambro's comprehensive expansion strategy in the field of dialyzers. The annual volume potential is more than one million dialyzers. For Gambro Healthcare this means a cost reduction and a treatment quality improvement.

The dialyzer is Gambro's synthetic Polyflux filter which is the most advanced filter on the market for hemodialysis and convective treatments where the selection of membrane structure and polymer materials are of prime importance. Gambro's concept for Polyamide S – the membrane of the Polyflux STM filter – results in unsurpassed removal capabilities in combination with superior biocompatibility.

The structural arrangement of the Polyamide S membrane with its three layer design and microdomain surface resembles that of nature's own biological membrane. This means that the immune system and coagulation cascade is left practically unaffected by blood/membrane contact. Clinical experience provides evidence of significant treatment benefits that suggest a reduced need for medication and hospital care, increased overall patient well-being and improved quality of life.

Gambro Renal Products

Gambro has a global leading position in products and systems for renal care including hemodialysis, peritoneal dialysis and renal intensive care. Gambro Renal Products has annual sales of about USD 900 M and has about 6,000 employees. Products are marketed under the Gambro and Hospal brands and mainly include filters, machines, concentrates and bloodlines for dialysis. Products and services are sold in more than 90 countries including own sales organizations in 29 countries. Development of products and production technology is focused into product centers of excellence in Germany, Italy and Sweden. The global manufacturing organization includes sites in North America, Europe, Asia and Australia. Research is performed by groups covering the main areas biology, medicine, treatment systems, membranes and devices. Research groups are located in Germany, France and Sweden.

November 8, 2000

For further information please contact:

Bengt Modéer, Senior Vice President, Corporate Communications, tel. +46-8-613 65 00,
+46-70-513 65 33

Cindy Lyman or Kerry Schneider, Citigate Dewe Rogerson, New York, tel. +1-212-688 6840

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. Gambro Healthcare is one of the leading providers of kidney dialysis services in the world with about 45,500 patients in 600 clinics worldwide. Gambro Renal Products comprises dialyzers, dialysis machines, blood lines and dialysis concentrates. Gambro BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 20 billion (USD 2.2 billion), has approximately 18,000 employees in some 40 countries.

Gambro AB

A public company (publ)
Reg no. 556041-8005
Hamngatan 2, P O Box 7373
SE-103 91 Stockholm
Sweden
Tel +46 8-613 65 00
Fax +46 8-611 28 30
info@gambro.com
www.gambro.com